{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:48:35Z","timestamp":1778575715720,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s12325-020-01443-6","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T12:02:47Z","timestamp":1594900967000},"page":"3839-3849","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of Prescribing Patterns of Renin\u2013Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure"],"prefix":"10.1007","volume":"37","author":[{"given":"Hyun-Jin","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2063-1542","authenticated-orcid":false,"given":"Sang-Ho","family":"Jo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won-Woo","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Oh","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyu-Hyung","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,16]]},"reference":[{"key":"1443_CR1","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","volume":"139","author":"EJ Benjamin","year":"2019","unstructured":"Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics\u20132019 update: a report from the American Heart Association. Circulation. 2019;139:e56\u2013528.","journal-title":"Circulation"},{"key":"1443_CR2","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129\u2013200.","journal-title":"Eur Heart J"},{"key":"1443_CR3","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137\u201361.","journal-title":"Circulation"},{"key":"1443_CR4","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1253\/circj.CJ-17-1386","volume":"82","author":"H Yaku","year":"2018","unstructured":"Yaku H, Ozasa N, Morimoto T, et al. Demographics, management, and in-hospital outcome of hospitalized acute heart failure syndrome patients in contemporary real clinical practice in Japan\u2014observations from the Prospective, Multicenter Kyoto Congestive Heart Failure (KCHF) Registry. Circ J. 2018;82:2811\u20139.","journal-title":"Circ J"},{"key":"1443_CR5","doi-asserted-by":"publisher","first-page":"e008789","DOI":"10.1161\/JAHA.118.008789","volume":"7","author":"LG Gilstrap","year":"2018","unstructured":"Gilstrap LG, Stevenson LW, Small R, et al. Reasons for guideline nonadherence at heart failure discharge. J Am Heart Assoc. 2018;7:e008789.","journal-title":"J Am Heart Assoc"},{"key":"1443_CR6","doi-asserted-by":"publisher","first-page":"e1008","DOI":"10.1016\/S2214-109X(18)30306-1","volume":"6","author":"TK Teng","year":"2018","unstructured":"Teng TK, Tromp J, Tay WT, et al. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. Lancet Glob Health. 2018;6:e1008\u201318.","journal-title":"Lancet Glob Health"},{"key":"1443_CR7","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1253\/circj.CJ-18-0073","volume":"82","author":"T Nagai","year":"2018","unstructured":"Nagai T, Yoshikawa T, Saito Y, et al. Clinical characteristics, management, and outcomes of Japanese patients hospitalized for heart failure with preserved ejection fraction\u2014a report from the Japanese Heart Failure Syndrome With Preserved Ejection Fraction (JASPER) Registry. Circ J. 2018;82:1534\u201345.","journal-title":"Circ J"},{"key":"1443_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gheart.2012.12.006","volume":"8","author":"SS Mahmood","year":"2013","unstructured":"Mahmood SS, Wang TJ. The epidemiology of congestive heart failure: the Framingham Heart Study perspective. Glob Heart. 2013;8:77\u201382.","journal-title":"Glob Heart"},{"key":"1443_CR9","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1253\/circj.CJ-16-1345","volume":"81","author":"HL Kim","year":"2017","unstructured":"Kim HL, Kim MA, Choi DJ, et al. Gender difference in the prognostic value of N-terminal Pro-B type natriuretic peptide in patients with heart failure\u2014a report from the Korean Heart Failure Registry (KorHF). Circ J. 2017;81:1329\u201336.","journal-title":"Circ J"},{"key":"1443_CR10","first-page":"S1","volume":"39","author":"National Kidney Foundation","year":"2002","unstructured":"National Kidney Foundation. K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1\u2013266.","journal-title":"Am J Kidney Dis"},{"key":"1443_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/ejhf.679","volume":"19","author":"G Targher","year":"2017","unstructured":"Targher G, Dauriz M, Laroche C, et al. In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19:54\u201365.","journal-title":"Eur J Heart Fail"},{"key":"1443_CR12","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","volume":"362","author":"CB Granger","year":"2003","unstructured":"Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772\u20136.","journal-title":"Lancet"},{"key":"1443_CR13","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G, Valsartan Heart Failure Trial I. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667\u201375.","journal-title":"N Engl J Med"},{"key":"1443_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"S Yusuf","year":"1991","unstructured":"SOLVD Investigators, Yusuf S, Pitt B, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293\u2013302.","journal-title":"N Engl J Med"},{"key":"1443_CR15","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","volume":"100","author":"M Packer","year":"1999","unstructured":"Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100:2312\u20138.","journal-title":"Circulation"},{"key":"1443_CR16","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","volume":"106","author":"M Packer","year":"2002","unstructured":"Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194\u20139.","journal-title":"Circulation"},{"key":"1443_CR17","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709\u201317.","journal-title":"N Engl J Med"},{"key":"1443_CR18","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","volume":"27","author":"JG Cleland","year":"2006","unstructured":"Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338\u201345.","journal-title":"Eur Heart J"},{"key":"1443_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1054\/jcaf.2001.26896","volume":"7","author":"KW Dauterman","year":"2001","unstructured":"Dauterman KW, Go AS, Rowell R, et al. Congestive heart failure with preserved systolic function in a statewide sample of community hospitals. J Card Fail. 2001;7:221\u20138.","journal-title":"J Card Fail"},{"key":"1443_CR20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1067\/mhj.2002.124058","volume":"144","author":"A Ahmed","year":"2002","unstructured":"Ahmed A, Roseman JM, Duxbury AS, Allman RM, DeLong JF. Correlates and outcomes of preserved left ventricular systolic function among older adults hospitalized with heart failure. Am Heart J. 2002;144:365\u201372.","journal-title":"Am Heart J"},{"key":"1443_CR21","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777\u201381.","journal-title":"Lancet"},{"key":"1443_CR22","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","volume":"359","author":"BM Massie","year":"2008","unstructured":"Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456\u201367.","journal-title":"N Engl J Med"},{"key":"1443_CR23","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.jacc.2009.02.046","volume":"53","author":"DJ van Veldhuisen","year":"2009","unstructured":"van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol. 2009;53:2150\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"1443_CR24","doi-asserted-by":"publisher","first-page":"e13317","DOI":"10.1111\/ijcp.13317","volume":"73","author":"JJ Egido","year":"2019","unstructured":"Egido JJ, Gomez R, Romero SP, et al. Treatment with renin-angiotensin system inhibitors and prognosis of heart failure with preserved ejection fraction: a propensity-matched study in the community. Int J Clin Pract. 2019;73:e13317.","journal-title":"Int J Clin Pract"},{"key":"1443_CR25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/heartjnl-2017-311652","volume":"104","author":"SL Zheng","year":"2018","unstructured":"Zheng SL, Chan FT, Nabeebaccus AA, et al. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart. 2018;104:407\u201315.","journal-title":"Heart"},{"key":"1443_CR26","doi-asserted-by":"publisher","first-page":"238","DOI":"10.4070\/kcj.2018.0259","volume":"49","author":"SH Kim","year":"2019","unstructured":"Kim SH, Yun SC, Park JJ, et al. Beta-blockers in patients with heart failure with preserved ejection fraction: results from the Korea acute heart failure (KorAHF) Registry. Korean Circ J. 2019;49:238\u201348.","journal-title":"Korean Circ J"},{"issue":"1462\u20131469","key":"1443_CR27","first-page":"e1468","volume":"32","author":"JJ Park","year":"2019","unstructured":"Park JJ, Choi HM, Hwang IC, et al. Myocardial strain for identification of beta-blocker responders in heart failure with preserved ejection fraction. J Am Soc Echocardiogr. 2019;32(1462\u20131469):e1468.","journal-title":"J Am Soc Echocardiogr"},{"key":"1443_CR28","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jchf.2017.12.014","volume":"6","author":"G Savarese","year":"2018","unstructured":"Savarese G, Orsini N, Hage C, et al. Utilizing NT-proBNP for eligibility and enrichment in trials in HFpEF, HFmrEF, and HFrEF. JACC Heart Fail. 2018;6:246\u201356.","journal-title":"JACC Heart Fail"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01443-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-020-01443-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01443-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T23:08:27Z","timestamp":1626390507000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-020-01443-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,16]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["1443"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01443-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,16]]},"assertion":[{"value":"12 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}